Axa cut its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 42.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 279,100 shares of the biopharmaceutical company’s stock after selling 209,750 shares during the quarter. Axa owned approximately 0.21% of Celldex Therapeutics worth $793,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Voya Investment Management LLC grew its holdings in shares of Celldex Therapeutics by 17.4% during the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 7,499 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Celldex Therapeutics by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 99,535 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 21,355 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Celldex Therapeutics by 3.6% during the third quarter. Bank of New York Mellon Corp now owns 622,430 shares of the biopharmaceutical company’s stock valued at $1,780,000 after purchasing an additional 21,905 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Celldex Therapeutics by 13.9% during the second quarter. California State Teachers Retirement System now owns 214,400 shares of the biopharmaceutical company’s stock valued at $530,000 after purchasing an additional 26,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Celldex Therapeutics by 3.6% during the third quarter. Dimensional Fund Advisors LP now owns 861,790 shares of the biopharmaceutical company’s stock valued at $2,465,000 after purchasing an additional 29,604 shares during the last quarter. 55.45% of the stock is owned by institutional investors.
Several equities analysts have recently commented on CLDX shares. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, March 7th. WBB Securities reissued a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, December 6th. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the stock a “buy” rating in a report on Friday, February 9th. Finally, Leerink Swann reissued a “market perform” rating and issued a $3.00 price objective (down from $4.00) on shares of Celldex Therapeutics in a report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.38.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.08. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The business had revenue of $3.50 million during the quarter, compared to analyst estimates of $1.49 million. During the same period in the prior year, the company posted ($0.30) EPS. The business’s revenue for the quarter was up 87.2% compared to the same quarter last year. sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -0.72 EPS for the current year.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
